Last updated on August 2019

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis


Brief description of study

The purpose of this study is to assess the efficacy and safety of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).

 

Clinical Study Identifier: TX227894

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

13801 Bruce B Downs Blvd. Suite 505 Tampa, FL USA
  Connect »